Horiguchi Jun, Iino Yuichi, Koibuchi Yukio, Yokoe Takao, Takei Hiroyuki, Yamakawa Michitaka, Nakajima Takashi, Oyama Tetsunari, Ando Tatsumasa, Ishida Tsunehiro, Endo Keiichi, Takai Yoshiki, Suzuki Hideo, Fujii Takanao, Yokomori Tadahiro, Morishita Yasuo
Second Department of Surgery, Gunma University Faculty of Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma 371-8511, Japan.
Breast Cancer. 2002;9(2):160-5. doi: 10.1007/BF02967581.
Breast-conserving therapy has been widely utilized as a treatment option for women with early breast cancer. However, no randomized study comparing modified radical mastectomy and breast-conserving therapy has been conducted in Japan.
Two hundred and twenty-eight Japanese women with early breast cancer enrolled in the Gunma Breast Conserving Therapy Study between 1991 and 1994 were examined to determine whether there is any difference in disease-free survival or overall survival between radical mastectomy and breast-conserving therapy. After informed consent was obtained, a total of 119 patients underwent breast-conserving therapy and 109 underwent mastectomy.
Mastectomy was a more frequently utilized treatment than breast-conserving therapy in patients with clinical stage II lesions, older age, larger tumor size or shorter distance between tumor and nipple. The mean follow-up period for all patients was 81 months (median 86 months). There was no significant difference in overall survival or disease-free survival between breast-conserving therapy and mastectomy even after adjusting for the clinical stage of the disease. A multivariate analysis of tumor size, lymph node status, estrogen receptor status and operation method using the Cox proportion hazard model confirmed that only lymph node status was an independent prognostic factor.
Breast-conserving therapy is comparable to modified radical mastectomy in overall survival and disease-free survival.
保乳治疗已被广泛用作早期乳腺癌女性的一种治疗选择。然而,日本尚未进行比较改良根治性乳房切除术和保乳治疗的随机研究。
对1991年至1994年间参加群马保乳治疗研究的228名日本早期乳腺癌女性进行检查,以确定根治性乳房切除术和保乳治疗在无病生存率或总生存率方面是否存在差异。在获得知情同意后,共有119例患者接受了保乳治疗,109例接受了乳房切除术。
在临床II期病变、年龄较大、肿瘤尺寸较大或肿瘤与乳头之间距离较短的患者中,乳房切除术是比保乳治疗更常用的治疗方法。所有患者的平均随访期为81个月(中位数86个月)。即使在对疾病的临床分期进行调整后,保乳治疗和乳房切除术在总生存率或无病生存率方面也没有显著差异。使用Cox比例风险模型对肿瘤大小、淋巴结状态、雌激素受体状态和手术方法进行多变量分析证实,只有淋巴结状态是一个独立的预后因素。
保乳治疗在总生存率和无病生存率方面与改良根治性乳房切除术相当。